Physician profile
David J Davidson
NPI 1063679116
$265,182.78
in general payments reported to CMS, 2019-2025
32 companies · $41K in 2025
The $41K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $17K · 2021: $32K · 2022: $66K · 2023: $55K · 2024: $23K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Consulting Fee: $16K · Food and Beverage: $5,003 · Travel and Lodging: $224 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,238.19 |
| Consulting Fee | $15,785.00 |
| Food and Beverage | $5,002.98 |
| Travel and Lodging | $223.58 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $124,334.80 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $53,745.08 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $28,430.67 | 2020-2025 | Nexletol |
| Amryt Pharma Holdings LTD | $16,718.06 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $13,318.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $8,895.58 | 2019-2021 | |
| Ionis Pharmaceuticals, INC. | $8,658.77 | 2025 | Tryngolza |
| Heartflow, INC. | $6,750.00 | 2023-2025 | Ffrct |
| Akcea Therapeutics, INC. | $1,820.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.75 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $292.66 | 2021-2025 | Wainua, Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $203.79 | 2022-2025 | |
| Boston Scientific Corporation | $176.98 | 2022-2025 | Watchman Flx, Watchman Access System |
| Merck Sharp & Dohme LLC | $160.37 | 2023-2025 | Verquvo |
| Medtronic, INC. | $148.05 | 2021-2025 | Linq II, Corevalve Evolut R |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $145.52 | 2022-2024 | Camzyos |
| Abiomed | $141.71 | 2023-2025 | Impella |
| Janssen Pharmaceuticals, INC | $119.46 | 2023-2025 | Xarelto, Opsumit, Opsynvi |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $113.68 | 2025 | |
| Abbott Laboratories | $106.99 | 2022-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $94.72 | 2024 | |
| Bridgebio Pharma, INC. | $94.69 | 2025 | Attruby |
| Lilly USA, LLC | $49.91 | 2024 | Zepbound, Jardiance |
| Lexicon Pharmaceuticals, INC. | $39.56 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $37.94 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $30.85 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $24.80 | 2023 | Definity |
| Bayer Healthcare Pharmaceuticals INC. | $23.67 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.51 | 2024 | Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $16.65 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.